Secondary malignancies and quality of life after stem cell transplantation

Bone Marrow Transplantation

Volumn 35, Issue , 2005, Pages S83-S87

  Ortega, J J ^a   Olive T ^a   de Heredia, C D ^a   Llort, A ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

BMT (SCT); Children; Lymphoproliferative disorders; Quality of life; Secondary malignancies; Solid tumors

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; GYRASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER INCIDENCE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELLULAR IMMUNITY; COGNITIVE DEFECT; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG TOLERABILITY; FAMILY; GRAFT REJECTION; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MYELODYSPLASIA; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK FACTOR; SOCIAL SUPPORT; SOLID TUMOR; STEM CELL TRANSPLANTATION; T CELL DEPLETION; VIRUS REACTIVATION;

CHILD; CHILD, PRESCHOOL; HUMANS; LYMPHOMA; MYELODYSPLASTIC SYNDROMES; QUALITY OF LIFE; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 18144426123     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704854     Document Type: Article

References (35)

1. Bathia S, Ramsay NKC, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633-3639.
2. Lowsky R, Lipton J, Fyles G et al. Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol 1994; 12: 2187-2192.
3. Kolb HJ, Socié G, Duell T et al. Malignant neoplasms in longterm survivors of bone marrow transplantation. Ann Intern Med 1999; 131: 738-744.
4. Bathia S, Bathia R. Secondary malignancies after hematopoietic cell transplantation. In: KG Blume, SJ Forman, FR Appelbaum (eds). Thomas Hematopoietic Cell Transplantation, 3rd edn. Blackwell Publishers: Malden, Mass., 2004, 962-977 (Chapter 70).
5. Wheeler C, Khurshid A, Ibrahim J et al. Incidence of posttransplantation myelodysplasia/acute leukaemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patient undergoing autologous transplantation following cyclophosphamide, carmustine and etoposide. Leuk Lymphoma 2001; 40: 499-509.
6. Milligan DW, Ruiz de Elvvia MC, Kolb HJ et al. Secondary leukemia and myelodysplasia after autografting for lymphoma: results from the EBMT. Br J Haematol 1999; 106: 1020-1027.
7. Friedberg JW, Neuberg D, Stone RM et al. Outcome of patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3128-3136.
8. Curtis RE, travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multiinstitutional study. Blood 1999; 94: 2208-2216.
9. Socié G, Curtis RE, Deeg J et al. New malignant diseases after allogeneic marrow transplantation for childhood leukemia. J Clin Oncol 2000; 18: 348-357.
10. Gerritsen EJA, Stam ED, Hermans J et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders after non-HLA-identical BMT in children. Bone Marrow Transplant 1996; 18: 377-382.
11. van Esser JW, van Der HB, Meijer E et al. Epstein-Barr virus reactivation is a frequent event after allogeneic stem cell transplantation and quantitatively predicts EBV-lymphopproliferative disease following T-cell-depleted SCT. Blood 2001; 98: 972-978.
12. Shapiro RS, Chauvenet A, Mc Guire W et al. Treatment of B-cell lymphoproliferative disorders with interferon alpha and intravenous gammaglobulin. N Eng J Med 1988; 318: 1334-1335.
13. Dotti E, Rambaldi A, Fiocchi R et al. Anti-CD20 antibody (ritumab) administration in patients with late occurring lymphomas after solid organ. Haematologica 2001; 86: 618-623.
14. Straathof KC, Savoldo B, Heslop HE, Rooney CM. Immunotherapy for post-transplat lymphoproliferative diseases. Br J Haemat 2002; 118: 728-740.
15. Faye A, Quartier P, Regerre Y et al. Chimaeric anti-CD20 monoclonal antibody (Rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115: 112-118.
16. Rooney LM, Smith CA, Nug CYC et al. Use of gene-modified virus-specific T lymphocytes to control Epstein Barr-virusrelated lymphoproliferation. Lancet 1995; 345: 9-13.
17. Comoli P, Labirio M, Basso S et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant: recipients with evidence of active virus replication. Blood 2002; 99: 2592-2598.
18. Curtis SRE, Rowlings PA, Deeg HJ et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897-904.
19. Deeg H, Socié G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998; 91: 1833-1844.
20. Deeg HJ, Spocié G, Henry-Amar M et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87: 386-392.
21. Favre-Schmuzig G, Hofers S, Passweg S et al. Treatment of solid tumors following allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25: 895-898.
22. Syrjala K. Assessment of quality of life in hematopoietic cell transplantation recipients. In: KG Blume, SJ Forman, FR Appelbaum (eds). Thomas Hematopoietic Cell Transplantation, 3rd edn. Blackwell Publishers: Malden, Mass., 2004, 962-977 (Chapter 70).
23. Duell S, van Lint MT, Ljungmann P et al. Health and functional status of long-term survivors of bone marrow transplantation. Ann Intern Med 1997; 126: 184-192.
24. Bush NE, Donaldson GN, Haberman MH et al. Conditional quality of life after hematopoietic stem cell transplantation: a longitudinal follow-up of 415 patients. Biol Blood Marrow Transplant 2000; 6: 576-591.
25. Kanabar DJ, Attard-Montalto S, Saha V et al. Quality of life in survivors of childhood cancer after megatherapy with autologous bone marrow rescue. Ped Hematol Oncol 1995; 12: 29-36.
26. Felder-Puig R, Peters C, Matthers-Martin S et al. Physicosocial adjustment of pediatric patients after allogeneic stem cell transplantation. Bone Marrow Transplant 1999; 24: 75-80.
27. Nespoli L, Verrri AP, Locatelli F et al. The impact of pediatric bone marrow transplantation on quality of life. Qual Life Res 1995; 4: 233-240.
28. Badell I, Igual L, Gó mez P et al. Quality of life in young adults having received a BMT during childhood: a GETMON study. Bone Marrow Transplant 1998; 21 (Suppl. 2): S68-S71.
29. Sanders JE, Syrkala KL, Hoffmister PH et al. Quality of life of adult survivors of childhood leukemia treated with chemotherapy or bone marrow transplant. Blood 2001; 98: 741a-742a.
30. Phipps S, Dunavant M, Garvie PA et al. Acute health-related quality of life in children undergoing stem-cell transplants. I-Descriptive outcomes. II Medical and demographic determinants. Bone Marrow Transplant 2002; 29: 425-442.
31. Barrera M, Boyd-Pringle LA, Sumbler K, Saunders S. Quality of life and behavioural adjustment after pediatric bone marrow transplantation. Bone Marrow Transplant 2000; 26: 427-435.
32. Kramer JH, Crittenden MR, De Santes H, Cowan MJ. Cognitive and adaptive behavior 1 and 3 years following bone marrow transplantation. Bone Marrow Transplant 1997; 19: 607-613.
33. Phipps S, Dunavant M, Srivastave DK et al. Cognitive and academic functioning in survivors of pediatric bone marrow transplantation. J Clin Oncol 2000; 18: 1004-1011.
34. Calaminus G, Weinspach S, Teske C, Göbel U. Quality of life in children and adolescents with cancer. Klin Pädiatr 2000; 212: 211-215.
35. Ortega JJ, Díaz de Heredia C, Olivé T et al. Allogeneic and autologous stem cell transplantation for AML in first remission: long-term results, late effects and quality of life. Pediatr Blood Cancer 2004; 43: 375 (Abstract).